Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer

Authors

Chenbo Zeng, Washington University School of Medicine in St. Louis
Suwanna Vangveravong, Washington University School of Medicine in St. Louis
Jonathan E. McDunn, Metabolon, Inc.
William G. Hawkins, Washington University School of Medicine in St. Louis
Robert H. Mach, Washington University School of Medicine in St. Louis

Journal

British Journal of Cancer

Publication Date

2013

Volume

109

Issue

9

Inclusive Pages

2368-2377

Document Type

Open Access Publication

DOI

10.1038/bjc.2013.593

Rights and Permissions

C Zeng, et al. Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer. British Journal of Cancer (2013) 109, 2368–2377. doi:10.1038/bjc.2013.593 www.bjcancer.com Copyright 2013 Cancer Research UK From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ 29 October 2013 This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

Recommended Citation

Zeng, Chenbo; Vangveravong, Suwanna; McDunn, Jonathan E.; Hawkins, William G.; and Mach, Robert H., "Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer." British Journal of Cancer. 109, 9. 2368-2377. (2013).
https://digitalcommons.wustl.edu/open_access_pubs/4051